Nasal-Spray Combined Vaccine for Covid and Flu Shows Protection
By: Colorado BioScience Association Date: 07/27/2021
Vivaldi Biosciences, a clinical-stage biotechnology company developing genetically engineered intranasal vaccines for viral respiratory
diseases, today announced positive preclinical data supporting further development of Delta-19, its combination vaccine for protection against COVID-19 and all strains of influenza. SARS-CoV-2, the virus
responsible for COVID-19, is expected to become endemic and adopt a seasonal pattern, much like influenza. Delta-19 is designed to address the dual disease threats of Covid-19 and influenza with a superior approach for greater protection against both diseases.
Studies of Delta-19 in the ferret model showed that 100% of the immunized animals generated high titers of SARS-CoV-2 spike-specific neutralizing antibodies, and 100% of the immunized animals were protected against challenge with a wild-type strain of SARS-CoV-2. Importantly, immunized ferrets had negligible amounts of SARS-CoV-2 challenge virus in their noses and mouths, while the virus proliferated to high levels in the noses and mouths of control ferrets. These findings suggest the possibility of
achieving sterilizing immunity with Delta-19, preventing replication of SARS-CoV-2 in the upper respiratory tract and transmission to other individuals.
Vivaldi Biosciences already has shown in clinical trials that the influenza vaccine component of Delta-19 is safe, immunogenic, and generates broadly cross-protective antibodies to diverse influenza strains.
Delta-19 builds on Vivaldi Biosciences’ DeltaFLU universal influenza vaccine, which has been successfully evaluated in four Phase 1 and 2 clinical trials. DeltaFLU shows potential for universal protection against
all influenza A and B virus strains, including drifted seasonal influenza strains and emerging pandemic strains.
Find out more in the press release.